Website Notice Block

Press Releases

Date Title and Summary View
Toggle Summary MediWound to Present at the Oppenheimer 27th Annual Healthcare Conference
YAVNE, Israel, March 13, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the Oppenheimer 27th Annual Healthcare Conference taking place from March 21-22...
View HTML
Toggle Summary Cost Analysis Demonstrating Significant Health Care Savings Utilizing NexoBrid® in Burn Management Published in BioMed Research International
YAVNE, Israel, March 03, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announces that outcomes from an independent cost analysis review utilizing NexoBrid in severe burn management compared with sta...
View HTML
Toggle Summary MediWound Reports 2016 Fourth Quarter and Full Year Financial Results
YAVNE, Israel, Feb. 21, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three and 12 months ended December 31, 2016. Highlights of the fourth quarter of 2016 and recen...
View HTML
Toggle Summary MediWound to Host 2016 Fourth Quarter and Full Year Financial Results Conference Call on February 21, 2017 at 8:30 a.m. Eastern Time
YAVNE, Israel, Feb. 14, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announces that the Company will release financial results for the three and twelve months ended December 31, 2016, at 7:00 a.m. ...
View HTML
Toggle Summary Favorable Results from NexoBrid Phase 2 Pharmacokinetic Clinical Study Support Treatment of Severe Burns Covering up to 30% of Total Body Surface Area
YAVNE, Israel , Feb. 09, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces positive results from a phase 2 study that evaluated the safety, pharmacokinetics (transcutaneous absorption) and efficacy ...
View HTML
Toggle Summary MediWound Initiates Second Stage of European Pediatric Phase 3 Study of NexoBrid® Expanding Treatment of Severe Burns to Children Age One to Four
YAVNE, Israel, Feb. 06, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that the European Medicines Agency (EMA) has endorsed the extension of the Children Innovative Debridement Study (CIDS) popu...
View HTML
Toggle Summary MediWound Reports Final Positive Results of Phase 2 Clinical Trial of EscharEx for the Debridement of Chronic and Hard-to-Heal Wounds
YAVNE, Israel, Jan. 31, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces final positive results from the Company's second Phase 2 clinical trial evaluating EscharEx® for debridement of dead or...
View HTML
Toggle Summary MediWound Granted U.S. Patent for MWPC003 for the Treatment of Connective Tissue Diseases
YAVNE, Israel, Dec. 20, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that the United States Patent and Trademark Office (USPTO) has issued patent Number 9,511,126 with claims related to the Com...
View HTML
Toggle Summary Abstract Highlighting NexoBrid® in Burn Mass Casualties Awarded "Best Poster" at the International Disaster and Military Medicine Conference
YAVNE, Israel, Nov. 18, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that an abstract highlighting the merits of NexoBrid® in the management of burns in mass casualty incidents was selecte...
View HTML
Toggle Summary MediWound Reports Third Quarter 2016 Financial Results
YAVNE, Israel, Nov. 14, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three and nine months ended September 30, 2016. Highlights of the third quarter of 2016 include...
View HTML